"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT05345990","Treatment of Patients With Chronic Hepatitis B With Hepatitis B Immunoglobulins","HBIG","Recruiting","No Results Available","Chronic Hepatitis B","Drug: Human hepatitis B Immunoglobulin (Hepatect®CP/Zutectra®)","To evaluate the efficacy of 12-weeks treatment with hepatitis B immunoglobulins in two different cohorts of patients with chronic hepatitis B defined by the proportion of subjects being HBsAg negative at treatment week 12|To analyze the change/decline of HBsAg during treatment|To evaluate the post-treatment HBsAg kinetics/response|To determine HBV-DNA levels during and after treatment with hepatitis B immunoglobulins|To evaluate the biochemical disease activity (normalization of serum ALT levels)|To determine the quality of life by SF-36 questionnaire|Assessment of safety by collection of adverse events (AEs) as frequencies (absolute/relative).","Hannover Medical School|Biotest","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HBIGforcure|2021-005362-18","August 15, 2022","November 2024","May 2025","April 26, 2022",,"October 10, 2023","Hannover Medical School, Department for Gastroenterology, Hepatology and Endocrinology, Hannover, Lower Saxony, Germany",,"https://ClinicalTrials.gov/show/NCT05345990"
2,"NCT02964910","A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Chronic Hepatitis B Patients )",,"Completed","Has Results","Hepatitis E","Biological: Recombinant Hepatitis E Vaccine (Escherichia Coli)","Number of Participants Whose Anti-HEV Antibody Seroconverted at One Month After The Third Dose|Geometric Mean Concentrations of Anti-HEV Antibody at One Month After The Third Dose|Number of Participants With Changes in Liver Function Index Before and One Month After the First Dose|Number of Participants With Changes in Liver Function Index Before and One Month After the Third Dose|Number of Participants With Changes in Liver Function Index Before The First Dose and One Month After the Third Dose|Number of Participants Who Experienced Any Adverse Reactions/Events|Number of Participants Who Experienced Solicited Adverse Reactions/Events|Number of Participants Who Experienced Solicited Local Adverse Reactions/Events|Number of Participants Who Experienced Solicited System Adverse Reactions/Events|Number of Participants Who Experienced Unsolicited Adverse Reactions/Events","Xiamen Innovax Biotech Co., Ltd","All","30 Years and older   (Adult, Older Adult)","Phase 4","475","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PRO-HE-009","August 2016","August 2017","December 2017","November 16, 2016","July 25, 2019","July 25, 2019","Rushan Center for Disease Control and Prevention, Weihai, Shandong, China","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/10/NCT02964910/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02964910"
3,"NCT04188223","Safety and Immunogenicity Following Recombinant Hepatitis B (Bio Farma) Vaccine in Adults & Children",,"Completed","No Results Available","Hepatitis B","Biological: Recombinant Hepatitis B (Bio Farma) Vaccine|Biological: Recombinant Hepatitis B (Bio Farma) Vaccine®","Number of subjects with Immediate reaction|percentage of subjects with Immediate reaction|Number of subjects with Adverse Events from 1 day to 28 days after vaccination|Percentage of subjects with Adverse Events from 1 day to 28 days after vaccination|Number of subjects with Serious Adverse Events from 1 day to 28 days after vaccination|Percentage of subjects with serious Adverse Events from 1 day to 28 days after vaccination|Number of Lab Deviation for adults subjects in 7 days of immunization|Safety Comparison between each intervention group|Protectivity of Hepatitis B vaccine (number of subject with protective anti HbsAg)|Protectivity of Hepatitis B vaccine (4 times increasing antibody)|Protectivity of Hepatitis B vaccine (Geometic Mean Titers)|Anti-HBs description between groups","PT Bio Farma","All","10 Years to 40 Years   (Child, Adult)","Phase 1","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Hep B 0119","December 3, 2019","July 16, 2020","July 16, 2020","December 5, 2019",,"August 1, 2022","Hasan Sadikin Hospital, Bandung, West Java, Indonesia",,"https://ClinicalTrials.gov/show/NCT04188223"
4,"NCT03219203","Immunologic Response of Hepatitis B Vaccine",,"Unknown status","No Results Available","Hepatitis B","Biological: Hepatitis B vaccine","Immunologic response to single dose versus 3-dose series of HBV vaccination in HIV-infected adults|Anamnestic response at week 4|Percentage of responders (with anti-HBs Ab ≥ 10 mIU/mL) at month 12|Intensity and frequency of vaccine adverse event (AE)","Chiang Mai University","All","18 Years to 25 Years   (Adult)","Phase 4","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","4564","July 1, 2017","July 1, 2018","October 1, 2018","July 17, 2017",,"July 17, 2017","Maharaj Nakorn Chiang Mai Hospital, Department of medicine, Chiang Mai University, Muang, Chiang Mai, Chiang Mai, Thailand",,"https://ClinicalTrials.gov/show/NCT03219203"
5,"NCT05404919","Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates","INHIBITOR","Recruiting","No Results Available","Lung Transplant|Hepatitis B","Drug: Hepatitis B Immune Globulin and entecavir, tenofovir disoproxil, or tenofovir alafenamide","Rate of HBV viremia|Time to undetectable HV DNA|Rate of acute HBV-associated hepatitis|Rate of persistent HBV surface antigen positivity|One year patient survival|One year graft survival","University of Pennsylvania","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","851257","September 6, 2022","August 2025","August 2032","June 3, 2022",,"October 4, 2023","Hospital of University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT05404919"
6,"NCT04503993","Healthy Planet Hepatitis B",,"Completed","No Results Available","Hepatitis B","Other: Hepatitis B surface antigen, Hepatitis B core antibody, and Hepatitis B surface antibody","Completion of hepatitis B order panel|Linkage to care of those found to be infected with hepatitis B","University of California, Davis","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","5004","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","1423112","February 25, 2020","July 24, 2021","December 31, 2021","August 7, 2020",,"May 10, 2022","UC Davis Medical Center, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT04503993"
7,"NCT03316313","Hepatitis C Screening in the Primary Care Setting",,"Completed","No Results Available","Hepatitis C","Diagnostic Test: Hepatitis C Antibody","Number of Patients Screened for Hepatitis C","New York Institute of Technology","All","50 Years to 71 Years   (Adult, Older Adult)",,"503","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","BHS-1194","June 2016","October 2016","April 2017","October 20, 2017",,"November 19, 2018",,,"https://ClinicalTrials.gov/show/NCT03316313"
8,"NCT02316444","Strategies for the Prevention of Hepatitis B Among HIV Infected Patients in Uganda",,"Completed","No Results Available","HIV/AIDS and Infections","Biological: Hepatitis B vaccine","Hepatitis B virus (HBV) vaccine response|Loss to follow-up (HAART naive vs. HAART exposed individuals)","Fred Hutchinson Cancer Center|Makerere University|Uganda Cancer Institute","All","18 Years and older   (Adult, Older Adult)","Phase 4","132","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","U010","November 2015","April 28, 2017","April 28, 2017","December 12, 2014",,"January 25, 2019","Mulago National referral hospital, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT02316444"
9,"NCT04405024","Pilot Study on the Feasibility of Systematic Hepatitis C Screening of Hospitalized Patients","HOSPI-VHC","Recruiting","No Results Available","Hepatitis C","Diagnostic Test: Hepatitis C testing","potential patient versus|HCV positive|Follow-up|Polymerase chain reaction (PCR)|Viral risk factor|hepatic fibrosis|treatment initiation","Centre Hospitalier Intercommunal Creteil|Association Nationale des Hépato-Gastroentérologues des Hôpitaux Généraux","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2500","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HOSPI-VHC|2019-A03309-48","September 21, 2020","June 21, 2024","August 21, 2024","May 28, 2020",,"October 31, 2023","CHI Créteil, Créteil, France|Grand Hôpital de l'Est Francilien - Site de Marne-la-Vallée, Jossigny, France|CH Meaux, Meaux, France|CHIV, Villeneuve-Saint-Georges, France",,"https://ClinicalTrials.gov/show/NCT04405024"
10,"NCT03149874","Accelerated Vaccination Schedule Against Hepatitis B Virus With Combined Hepatitis A and B Vaccine Among Hemodialysis Patients",,"Completed","No Results Available","Hepatitis B|Hemodialysis Complication","Drug: Hepatitis B recombinant DNA vaccine|Drug: Combined hepatitis A and B vaccine","Hepatitis B virus Seroprotection after one month|Hepatitis B virus Seroprotection after three months|Fever|Pain scale","Benha University|New Jeddah Clinic Hospital","All","19 Years and older   (Adult, Older Adult)","Not Applicable","114","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","BN-0517","December 1, 2014","April 30, 2017","May 1, 2017","May 11, 2017",,"February 8, 2023",,,"https://ClinicalTrials.gov/show/NCT03149874"
11,"NCT01634919","Histologic Changes and Noninvasive Assessment in Hepatitis C Patients Treated With Peginterferon Alpha-2a and Ribavirin",,"Completed","No Results Available","Chronic Hepatitis C","Device: chronic hepatitis C","Anti-fibrotic response|Histologic and noninvasive fibrosis assessments","Seoul National University Boramae Hospital|Roche Pharma AG","All","20 Years and older   (Adult, Older Adult)",,"55","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","06-2012-74","July 2012","February 17, 2017","February 9, 2018","July 6, 2012",,"March 20, 2020","Seoul Metropolitan Government Boramae Medical Center, Seoul, Korea, Republic of|SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01634919"
12,"NCT02603055","A Clinical Trial to Evaluate a Recombinant Hepatitis E Vaccine in Healthy Adults",,"Completed","No Results Available","Hepatitis E","Biological: 30μg/0.5ml Hepatitis E vaccine|Biological: 30μg/0.5ml Recombinant Hepatitis E vaccine","Occurrence of adverse reactions after vaccination|The geometric mean concentration of antibody against Hepatitis E responses to the Hepatitis E vaccine|Occurrence of adverse events after each vaccination|Occurrence of serious adverse events after the vaccination.|The positive rates of antibody against Hepatitis E responses to the Hepatitis E vaccine.","Jiangsu Province Centers for Disease Control and Prevention|Changchun Institute of Biological Products Co., Ltd.","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Phase 1","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","JSVCT025","July 2015","April 2016","August 2016","November 11, 2015",,"September 1, 2016","Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT02603055"
13,"NCT04437277","Screening for Chronic Hepatitis C Virus in Hospitalized Patients","DeViCHO","Completed","No Results Available","Hepatitis C","Diagnostic Test: Hepatitis C, serology","Prevalence of hepatitis C through the different department of Saint Joseph Hospital|number of viremic patients with risk factors|number of viremic patients without risk factors|number of patients who refuse viral screening","Hospital St. Joseph, Marseille, France","All","18 Years and older   (Adult, Older Adult)","Not Applicable","5000","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2018-A02595-50","November 22, 2019","November 30, 2021","November 30, 2021","June 18, 2020",,"January 11, 2022","Hopital Saint Joseph, Marseille, Paca, France",,"https://ClinicalTrials.gov/show/NCT04437277"
14,"NCT02152709","Study of Evaluating Safety and Immunogenicity of 10µg/0.5ml Hepatitis B Vaccine",,"Completed","No Results Available","Hepatitis B","Biological: 3 dose of 10µg/0.5ml hepatitis B vaccine|Biological: 3 dose of 5µg/0.5ml hepatitis B vaccine","Number of subjects with adverse events|Geometric mean concentration of anti-hepatitis B virus surface antigen antibody|The rate of hepatitis B virus perinatal transmission|Geometric mean concentration of anti-hepatitis B virus surface antigen antibody after the second dose of hepatitis B vaccination","Jiangsu Province Centers for Disease Control and Prevention|Beijing Tiantan Biological Products Co., Ltd.","All","1 Day to 75 Years   (Child, Adult, Older Adult)","Phase 3","1537","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","JSEPI-003","November 2008","March 2010","October 2010","June 2, 2014",,"June 2, 2014","Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT02152709"
15,"NCT03867643","Efficacy of Hepatitis B Vaccine Boosters Among Neonatally Vaccinated Children in Chongqing",,"Recruiting","No Results Available","Hepatitis B Vaccine Adverse Reaction","Biological: hepatitis B vaccine(HepB)","HBsAb positive rate|HBsAg-specific T cell response|HBsAb protective efficacy","Children's Hospital of Chongqing Medical University","All","1 Year to 15 Years   (Child)",,"80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2019-09","July 9, 2021","September 9, 2021","December 31, 2025","March 8, 2019",,"March 10, 2022","Children's Hospital of Chongqing Medical University, Chongqing, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT03867643"
16,"NCT04326803","Hepatitis B en Haitian Immigrants in Chile: Molecular Characterization and Determination of Vaccine Response",,"Unknown status","No Results Available","Hepatitis B","Biological: Hepatitis B recombinant vaccine","Response rate","Pontificia Universidad Catolica de Chile","All","18 Years and older   (Adult, Older Adult)","Phase 4","200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","180814005|1191389","June 1, 2020","June 30, 2022","December 30, 2023","March 30, 2020",,"March 31, 2020",,,"https://ClinicalTrials.gov/show/NCT04326803"
17,"NCT03396458","Hepatitis B Prevalence in the Turkish Population Living in Middle Limburg","HBVTR","Unknown status","No Results Available","Hepatitis B","Diagnostic Test: Hepatitis B serology|Other: Questionnaire","Seroprevalence of current HBV infection in the Turkish population|Seroprevalence of protective antibodies against HBV infection in the Turkish population|Assess risk factors for past or current HBV infecion in the Turkish population","Hasselt University","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","HBVTR-1.0","September 1, 2017","August 31, 2020","August 31, 2020","January 11, 2018",,"January 27, 2020","Ziekenhuis Oost-Limburg, Genk, Limburg, Belgium",,"https://ClinicalTrials.gov/show/NCT03396458"
18,"NCT01446978","Three Doses of Hepatitis A Vaccine in Patients With Immunomodulating Drugs",,"Unknown status","No Results Available","Vaccine Response Impaired","Biological: hepatitis A vaccine","seroconversion after the first dose/doses of hepatitis A vaccine|seroconversion rates after three doses of hepatitis A vaccine","Sormland County Council, Sweden","All","18 Years and older   (Adult, Older Adult)","Phase 2","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Rombo - 2","September 2011","August 2016","August 2016","October 5, 2011",,"November 18, 2015","Dept infectious diseases, Eskilstuna, Sweden|Department of infectious diseases, Stockholm, Sweden|Dept infectious diseases, Uppsala, Sweden|Dept infectious diseases, Örebro, Sweden",,"https://ClinicalTrials.gov/show/NCT01446978"
19,"NCT03168412","A Study on the Recombinant Hepatitis E Vaccine (Escherichia Coli) (Accelerated Vaccination Schedule)",,"Completed","No Results Available","Hepatitis E","Biological: Recombinant Hepatitis E Vaccine (Escherichia Coli)","Anti-HEV antibody of Experimental Group|Adverse reactions/events of Experimental Group and Control Group|Anti-HEV antibody of Control Group","Xiamen Innovax Biotech Co., Ltd","All","18 Years and older   (Adult, Older Adult)","Phase 4","125","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PRO-HE-008","May 25, 2017","July 15, 2018","November 28, 2018","May 30, 2017",,"February 21, 2019","Changshan Center for Disease Control and Prevention, Quzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT03168412"
20,"NCT04071379","Comparison of Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) With Pentabio® Vaccine Primed With Recombinant Hepatitis B",,"Completed","No Results Available","Immunogenicity|Safety","Biological: Recombinant Hepatitis B + DTP-HB-Hib|Biological: Hep B + Pentabio (registered)","To evaluate protectivity of DTP-HB-Hib Vaccine (Bio Farma) with new Hepatitis B bulk|Describes antibody response to diphtheria toxoid, tetanus toxoid in both group with the evaluation criteria|Serological response to the pertussis component (agglutinins)|Geometric mean of anti-HbsAg|Serological response to Hib/PRP|Seroconversion","PT Bio Farma","All","0 Days to 3 Days   (Child)","Phase 3","220","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Penta BS19","October 13, 2020","April 6, 2021","December 16, 2021","August 28, 2019",,"January 18, 2022","Garuda Primary Health Centre, Bandung, West Java, Indonesia|Ibrahim Adjie Primary Health Centre, Bandung, West Java, Indonesia|Puter Primary Health Care, Bandung, West Java, Indonesia",,"https://ClinicalTrials.gov/show/NCT04071379"
21,"NCT01933412","Efficacy and Safety of Hepatitis B Vaccine in Chronic Kidney Disease Patients",,"Unknown status","No Results Available","Chronic Kidney Disease|Hepatitis B","Biological: Sci-B-Vac Hepatitis B Vaccine|Biological: Engerix B Hepatitis B Vaccine","anti-Hepatitis B surface levels ≥ 10 IU/mL|anti-Hepatitis B surface antibody Geometric Mean Concentrations|52 week anti-Hepatitis B surface antibody Geometric Mean Concentrations|serum titer levels of anti-Hepatitis B surface antibodies|Adverse events","Tel-Aviv Sourasky Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","TLVMC1.2013","March 2012","August 2013",,"September 2, 2013",,"September 2, 2013","Tel Aviv Sourasky Medical Center Dialysis Unit, Tel Aviv, Israel",,"https://ClinicalTrials.gov/show/NCT01933412"
22,"NCT02417597","A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)",,"Completed","No Results Available","Hepatitis E","Biological: Recombinant Hepatitis E Vaccine (Escherichia Coli)","Adverse reactions/events|Anti-HEV antibody","Xiamen Innovax Biotech Co., Ltd|Xiamen University|Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 4","600","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PRO-HE-006","April 2015","May 2016","May 2016","April 15, 2015",,"May 18, 2016","Kaihua Center for Disease Control and Prevention, Quzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT02417597"
23,"NCT00792610","The Hepatitis B Vaccine Booster Response Among the Youth Who Had Completed Neonatal Hepatitis B Vaccines",,"Completed","Has Results","Hepatitis B","Biological: hepatitis B vaccine","Hepatitis B Surface Antibody Seroprotective Rate(Seroprotective: for Those Who Had Anti-HBs(Surface Antibody Against Hepatitis B) Titer Higher Than 10 mIU/mL)","National Taiwan University Hospital|National Science Council, Taiwan","All","18 Years to 23 Years   (Adult)","Not Applicable","127","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","200701049M|NSC96-2314-B-0020115","August 2007","January 2009","February 2009","November 18, 2008","September 24, 2009","October 6, 2009","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00792610"
24,"NCT03316807","Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults","HIV","Completed","Has Results","Hepatitis B Vaccine","Biological: 60 µg dose hepatitis B vaccine|Biological: 20 µg dose hepatitis B vaccine","Number and Percentage of Participants With Anti-HBs Seroconversion at Month 7|Anti-HBs Concentration at Month 7|Number and Percentage of Participants With Anti-HBs Seroconversion at Month 12|Anti-HBs Concentration at Month 12|Occurrence of Adverse Events After Vaccination|Serious Adverse Events (SAE) Occurred During 42 Month","Suping Wang|Centers for Disease Control and Prevention, China|Shanxi Medical University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","182","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention","2012ZX10002001003004004","October 2014","July 2015","July 2018","October 20, 2017","January 14, 2021","March 11, 2022",,,"https://ClinicalTrials.gov/show/NCT03316807"
25,"NCT03654664","To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine","VITHA-C","Completed","No Results Available","Hepatitis A Vaccine","Biological: Inactivated hepatitis A vaccine|Biological: Havrix Inj","Seroconversion rate|Antibody titer (GMT)","Boryung Pharmaceutical Co., Ltd","All","12 Months to 23 Months   (Child)","Phase 3","119","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","BR-HAV-CT-301","June 20, 2017","June 24, 2019","June 24, 2019","August 31, 2018",,"July 7, 2023","The Catholic University of Korea, Incheon St.Mary's Hospital, Incheon, Bupyeong-gu, Korea, Republic of|The Catholic University of Korea, St.Vincent's Hospital., Suwon-si, Gyeonggi-do, Korea, Republic of|Korea University Ansan Hospital, Ansan, Korea, Republic of|Chanwon Fatima Hospital, Changwon, Korea, Republic of|KeiMyung University Dongsan Medical Center, Daegu, Korea, Republic of|Gachon University Gil Hospital, Incheon, Korea, Republic of|Hanil General Hospital, Seoul, Korea, Republic of|Korea cancer center Hospital, Seoul, Korea, Republic of|Nowon Eulji Medical center , Eulji University, Seoul, Korea, Republic of|Wonju Sevrance Christian Hospital, Wonju, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03654664"
26,"NCT01146808","Adefovir Plus Vaccination in Transplant Patients Without Hepatitis B That Receive a Core Antibody Positive Liver",,"Completed","Has Results","Hepatitis B|Liver Transplantation","Drug: Adefovir dipivoxil and hepatitis B vaccination","Development of de Novo Hepatitis B Infection After Transplant With a Core Antibody Positive Liver|Proportion of Patients With a Sustained Hepatitis B Surface Antibody Titer > 500 IU/mL Prior to and After Vaccination|Proportion of Patients Who Develop de Novo Hepatitis B Infection Post ADV Withdrawal, Which Will be Assessed at 6 Months Post Withdrawal","Columbia University|Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","16","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAB8413|IN-US-103-0158","March 2006","September 2011","September 2012","June 22, 2010","March 15, 2017","August 10, 2021","Center for Liver Disease and Transplantation at Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01146808"
27,"NCT02963714","Immunogenicity of Hepatitis B Vaccination in Hemodialysis Patients",,"Completed","Has Results","Hepatitis B Vaccine","Biological: 60 µg dose hepatitis B vaccine|Biological: 20 µg dose hepatitis B vaccine","Anti-HBs Seroconversion Rate at Month 7|Anti-HBs Seroconversion Rate at Month 42|Anti-HBs Seroconversion Rate at Month 36|Anti-HBs Seroconversion Rate at Month 30|Anti-HBs Seroconversion Rate at Month 24|Anti-HBs Concentration at Month 7|Anti-HBs Concentration at Month 12|Anti-HBs Seroconversion Rate at Month 12|Occurrence of Adverse Events After Vaccination|Anti-HBs Seroconversion Rate at Month 18","Suping Wang|Centers for Disease Control and Prevention, China|Shanxi Medical University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","352","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2012ZX10002001003004001","December 2014","July 2015","July 2018","November 15, 2016","February 14, 2022","February 14, 2022",,,"https://ClinicalTrials.gov/show/NCT02963714"
28,"NCT02991599","Immunogenicity of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients",,"Completed","Has Results","Hepatitis B Vaccine","Biological: 60 µg dose hepatitis B vaccine|Biological: 20 µg dose hepatitis B vaccine","Number and Rate of Participants With Anti-HBs Seroconversion at Month 7|Anti-HBs Concentration at Month 7|Anti-HBs Concentration at Month 12|Number and Rate of Participants With Anti-HBs Seroconversion at Month 12|Occurrence of Adverse Events After Vaccination|Anti-HBs Concentration at Month 18|Number and Rate of Participants With Anti-HBs Seroconversion at Month 18|Anti-HBs Concentration at Month 30|Number and Rate of Participants With Anti-HBs Seroconversion at Month 30|Anti-HBs Concentration at Month 42|Number and Rate of Participants With Anti-HBs Seroconversion at Month 42","Shanxi Medical University|Centers for Disease Control and Prevention, China","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","196","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2012ZX10002001003004003","October 2014","July 2015","May 2018","December 13, 2016","July 30, 2019","December 23, 2021",,,"https://ClinicalTrials.gov/show/NCT02991599"
29,"NCT01014845","Clinical Trial of Recombinant Hepatitis E Vaccine",,"Completed","No Results Available","Hepatitis E","Biological: hepatitis E vaccine|Biological: Hepatitis B vaccine","Rate of confirmed hepatitis E cases|IgG anti-HEV seroconversion rate|Persistency of IgG anti-HEV","Xiamen University|Xiamen Innovax Biotech Co., Ltd|Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.|National Institute of Diagnostics and Vaccine Development in infectious disease|Jiangsu Provincial Center for Disease Control and Prevention","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Phase 3","112604","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Pro-HE-003|2006AA02A209","August 2007","October 2017","October 2017","November 17, 2009",,"July 13, 2020","Dongtai Center for Disease Control and Prevention, Dongtai, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT01014845"
30,"NCT04139850","The Establishment of Korean Hepatitis B Patients Cohort",,"Recruiting","No Results Available","Chronic Hepatitis B","Drug: Discontinuation of antiviral treatment in chronic hepatitis B cohort patients","Development of liver cirrhosis, decompensation or liver cancer|Safety and efficacy for patients with or without antiviral therapy","Yonsei University","All","19 Years and older   (Adult, Older Adult)",,"2000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","4-2015-0748","September 25, 2015","August 2026","August 2026","October 25, 2019",,"October 25, 2019","Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04139850"
31,"NCT02203357","A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Adults",,"Completed","Has Results","Hepatitis B","Biological: Hepatitis B vaccine","Immunogenicity of Hepatitis B Vaccine With Different Doses and Schedules in Healthy Young Adults","Peking University|Guangxi Center for Disease Control and Prevention|Liuzhou City Center for disease control and prevention|Shenzhen Kangtai Biological Products Co., LTD","All","18 Years to 25 Years   (Adult)","Phase 4","353","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HepB-2014","March 2014","June 2016","December 2016","July 29, 2014","October 3, 2019","October 18, 2019","Peking University, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02203357"
32,"NCT01251276","Hepatitis B Challenge Dose in Adults (V232-059-10)",,"Completed","Has Results","Hepatitis B","Biological: Modified Process Hepatitis B Vaccine","Percentage of Seroresponders Before and After the Challenge Vaccination|Percentage of Participants With One or More Adverse Experiences|Percentage of Participants Who Discontinued the Study Due to an Adverse Experience|Percentage of Participants With One or More Injection-site Adverse Experiences|Percentage of Participants With One or More Systemic Adverse Experiences|Percentage of Participants With One or More Serious Adverse Experiences","Merck Sharp & Dohme LLC","All","50 Years and older   (Adult, Older Adult)","Phase 3","204","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","V232-059-10|rHB01C|2006-003649-18","November 30, 2010","April 12, 2011","April 12, 2011","December 1, 2010","August 28, 2017","September 13, 2022",,,"https://ClinicalTrials.gov/show/NCT01251276"
33,"NCT01131065","Efficacy and Safety of Niuliva® for the Prevention of Hepatitis B Virus Recurrence in Newly Orthotopic Liver Transplant Recipients",,"Completed","Has Results","Hepatitis B|Liver Transplantation","Drug: Hepatitis B immune globulin","HBV Recurrence|HBsAb Pre-infusion Levels (Trough Levels Before Each Niuliva Administration)|Safety and Tolerance","Instituto Grifols, S.A.|Grifols Biologicals, LLC","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","15","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IG0907","July 2010","June 2014","June 2014","May 26, 2010","February 1, 2016","February 25, 2016","A.O.U. Policlinico Università di Modena e Reggio Emilia, Modena, Italy|Az. Ospedaliera Universitaria di Padova, Padova, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Italy|Az. Ospedaliera S.Giovanni Battista di Torino, Torino, Italy",,"https://ClinicalTrials.gov/show/NCT01131065"
34,"NCT03654677","To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine (VITHA-A)",,"Completed","No Results Available","Hepatitis A Vaccine","Biological: inactivated hepatitis A vaccine|Biological: Havrix Inj","Seroconversion rate","Boryung Pharmaceutical Co., Ltd","All","16 Years and older   (Child, Adult, Older Adult)","Phase 3","253","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","BR-HAV-CT-302","September 19, 2017","October 12, 2018","January 31, 2019","August 31, 2018",,"March 23, 2020","The Catholic University of Korea, Seoul St.Mary's Hospital, Seoul, Banpo-dong, Seocho-gu, Korea, Republic of|The Catholic University of Korea, Incheon St.Mary's Hospital, Incheon, Bupyeong-gu, Korea, Republic of|The Catholic University of Korea,Uijeongbu St.Mary's Hospital, Uijeongbu, Gyeonggi-do, Korea, Republic of|The Catholic University of Korea, Bucheon St.Mary's Hospital, Bucheon, Kyunggi-Do, Korea, Republic of|The Catholic University of Korea,Yeouido St.Mary's Hospital, Seoul, Yeongdeungpo-gu, Korea, Republic of|Hallym University Medical Center, Seoul, Yeongdeungpo-gu, Korea, Republic of|Soon chung hyang university hospita, Bucheon, Korea, Republic of|Inje university Ilsan Paik hospital, Ilsan, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of|Hanyang university medical center, Seoul, Korea, Republic of|Kyunghee university hospital, Seoul, Korea, Republic of|Soon Chun Hyang university hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03654677"
35,"NCT03951662","Immunology of HIV and Alcoholic Hepatitis",,"Withdrawn","No Results Available","HIV/AIDS|Alcoholic Hepatitis","Other: Alcoholic Hepatitis Group|Other: Heavy Drinking Controls without Hepatitis","Immune activation - Levels of sCD14, sCD163","Indiana University","All","18 Years and older   (Adult, Older Adult)",,"0","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","NIAAA 1UH2AA026218","July 1, 2020","September 30, 2020","September 30, 2020","May 15, 2019",,"January 22, 2021","Infectious Diseases Research Center, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT03951662"
36,"NCT02764671","Safety and Immunogenicity of Recombinant Hepatitis B Vaccines in the Neonates",,"Unknown status","No Results Available","Hepatitis|Hepatitis B|Liver Diseases|Digestive System Diseases","Biological: 10μg/0.5ml recombinant hepatitis B vaccine","Number of subjects with adverse events|Geometric mean titer of anti-hepatitis B virus surface antigen antibody","Shenzhen Kangtai Biological Products Co., LTD|Guangdong Provincial Institute of Biological Products And Materia Medica","All","up to 24 Hours   (Child)","Phase 4","5000","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","KT0012","May 2015","September 2020","September 2020","May 6, 2016",,"May 6, 2016","Gaozhou District Center for Disease Control and Prevention, Maoming, Guangdong, China|Xinxing District Center for Disease Control and Prevention, Yunfu, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02764671"
37,"NCT00440297","Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060)",,"Completed","Has Results","Hepatitis B Virus Infection","Biological: Comparator: modified process hepatitis B vaccine|Biological: Comparator: ENGERIX-B™","The Number of Seroprotected Participants to the Modified Process Hepatitis B Vaccine and ENGERIX-B™ (Currently Licensed Vaccine) at Month 7|The Number of Seroprotected Participants to the Modified Process Hepatitis B Vaccine and ENGERIX-B™ (Currently Licensed Vaccine) at Month 9|The Total Number of Participants With One or More Injection-Site Adverse Experiences|The Total Number of Participants With a Maximum Temperature >= 100.0F / 37.8C|The Total Number of Participants With Serious Vaccine-Related Clinical Adverse Experiences","Merck Sharp & Dohme LLC","All","18 Years and older   (Adult, Older Adult)","Phase 3","277","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","V232-060|2007_515","December 2006","May 2008","May 2008","February 27, 2007","July 8, 2009","April 13, 2017",,,"https://ClinicalTrials.gov/show/NCT00440297"
38,"NCT03393754","Immunogenicity and Safety of Sci-B-Vac® to Engerix-B® in Adults",,"Completed","Has Results","Hepatitis B Vaccines","Biological: Hepatitis B Vaccination","Seroprotection Rate (SPR) Defined as Percentage of Adults ≥ 18 Years Old Achieving Anti-HBs Levels of ≥10 mIU/mL in Serum at Study Day 196|Seroprotection Rate (SPR) Defined as Percentage of Adults ≥ 45 Years Old Achieving Anti-HBs Levels of ≥10 mIU/mL in Serum at Study Day 196|Percentage of Subject-reporting Solicited Local and Systemic Adverse Events (AEs)","VBI Vaccines Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","1607","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Sci-B-Vac-001|2017-001819-36","December 13, 2017","April 8, 2019","April 8, 2019","January 8, 2018","July 7, 2020","July 17, 2020","Accel Research Sites, Birmingham, Alabama, United States|Anaheim Clinical Trials, Anaheim, California, United States|Avail Clinical Research, DeLand, Florida, United States|Suncoast Research Group, Miami, Florida, United States|Clinical Research Atlanta, Atlanta, Georgia, United States|Advanced Clinical Research, Boise, Idaho, United States|Clinical Research Center of Nevada, Las Vegas, Nevada, United States|Rapid Medical Research, Cleveland, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Advanced Clinical Research, Salt Lake City, Utah, United States|Universitair Ziekenhuis Gent, Gent, Oost-Vlaanderen, Belgium|BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Canadian Center for Vaccinology, Halifax, Nova Scotia, Canada|Ottawa Hospital, Ottawa, Ontario, Canada|Medicore Research Inc, Sudbury, Ontario, Canada|McGill University Health Centre, Montreal, Quebec, Canada|CHU de Québec Université Laval, Quebec, Canada|Espoo Vaccine Research Clinic, Espoo, Finland|Helsinki South Vaccine Research Clinic, Helsinki, Finland|Järvenpää Vaccine Research Clinic, Järvenpää, Finland|Kokkola Vaccine Research Clinic, Kokkola, Finland|Oulu Vaccine Research Clinic, Oulu, Finland|Pori Vaccine Research Clinic, Pori, Finland|Seinäjoki Vaccine Research Clinic, Seinäjoki, Finland|Tampere Vaccine Research Clinic, Tampere, Finland|University of Tampere, Tampere, Finland|Turku Vaccine Research Clinic, Turku, Finland","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/54/NCT03393754/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/54/NCT03393754/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03393754"
39,"NCT03231605","Comparative Immunogenicity Study of Two Hepatitis A Vaccines",,"Unknown status","No Results Available","Hepatitis A","Biological: Hepatitis A Vaccine","To verify the protection rate and antibody quantity of experimental vaccine non-inferior than control vaccine.|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","China National Biotec Group Company Limited|Shaanxi Provincial Center for Disease Control and Prevention","All","18 Months to 24 Months   (Child)","Phase 4","300","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","91110000100010062X","July 26, 2017","August 31, 2017","December 29, 2017","July 27, 2017",,"August 1, 2017","Shanxi Provincial Center for Disease Control and Prevention, Yuncheng, Shanxi, China",,"https://ClinicalTrials.gov/show/NCT03231605"
40,"NCT04083157","Intra-dermal With Topical Imiquimod Pretreatment Versus Intra-muscular Hepatitis B Vaccination in IBD Patients",,"Completed","No Results Available","Inflammatory Bowel Diseases|Hepatitis B","Biological: Intradermal hepatitis B vaccine with imiquimod|Biological: Intramuscular hepatitis B vaccine with aqueous cream","Sero-protection rate to HBV|Injection site adverse effect of intradermal hepatitis B vaccine in IBD patients|Systemic adverse effect of intradermal hepatitis B vaccine in IBD patients|Sero-protection rate to HBV at 1 and 6 months after dose of vaccine|Percentage of good responder defined as anti-HBs ≥ 100 IU/L|Geometric mean concentration of anti-HBs at 1, 6 and 12 months after first dose of vaccine","The University of Hong Kong","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","104","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IBDHepBVaccine","August 12, 2019","December 30, 2020","December 30, 2021","September 10, 2019",,"May 18, 2022","Queen Mary Hospital, Hong Kong, China",,"https://ClinicalTrials.gov/show/NCT04083157"
41,"NCT00873652","Observational Study of Immune Response to Hepatitis B Childhood Booster",,"Completed","No Results Available","Healthy","Biological: Engerix B®, a recombinant hepatitis B vaccine","The percentage of participants completing an accelerated course of hepatitis B vaccination with 10 IU/ml Hepatitis B surface antigen specific antibodies (antiHBs) before and after the 'pre-school' booster dose of Hepatitis B vaccine.|To evaluate the percentage of participants who had serum antiHBs concentrations < 10 IU/ml at visit 1 who had a rise in serum antiHBs to 10 IU/ml at visit 2.|To evaluate the percentage of participants who had serum antiHBs concentrations < 10 IU/ml at visit 1 who had a rise in serum antiHBs to 100 IU/ml at visit 2.|To evaluate the serum antiHBs geometric mean concentrations (GMCs) at visit 1 and visit 2.","University of Oxford","All","41 Months to 7 Years   (Child)",,"28","Other","Observational","Observational Model: Cohort|Time Perspective: Other","OVG 2008/5","February 2009","January 2011","January 2011","April 1, 2009",,"December 8, 2017","Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Churchill Hospital, Oxford, Oxfordshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00873652"
42,"NCT05482295","Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III)",,"Not yet recruiting","No Results Available","Vaccine Reaction|Vaccine Adverse Reaction","Biological: Hepatitis B vaccine lot 1|Biological: Hepatitis B vaccine lot 2|Biological: Hepatitis B vaccine lot 3|Biological: Hepatitis B vaccine (registered)","Percentage of subjects with increasing antibody titer >= 4 times|Geometric Mean Titer (GMT)|Percentage of subjects with transition of seronegative to seropositive|Percentage of subjects with at least one immediate reaction|Percentage of subjects with at least one of these adverse events|Serious adverse event after vaccination|Comparison adverse events between Investigational Products (Hepatitis B) and Control|Comparison of adverse events between each lot number of Recombinant Hepatitis B","PT Bio Farma|RS Umum Pusat Sanglah, Denpasar","All","10 Years to 40 Years   (Child, Adult)","Phase 3","540","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Hep B 0322","October 2022","November 2022","December 2022","August 1, 2022",,"September 19, 2022",,,"https://ClinicalTrials.gov/show/NCT05482295"
43,"NCT04204447","Hepatitis C-Video vs. Brochure Education Delivery",,"Completed","No Results Available","Hepatitis C","Other: Hepatitis C Educational Brochure|Other: Hepatitis C Educational Video","Improved score on HCV Knowledge Questionnaire","State University of New York at Buffalo","All","18 Years and older   (Adult, Older Adult)","Not Applicable","176","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","STUDY00002677","November 27, 2019","October 31, 2020","October 31, 2020","December 19, 2019",,"April 19, 2022","University at Buffalo, Buffalo, New York, United States|BestSelf Behavioral Health, Orchard Park, New York, United States",,"https://ClinicalTrials.gov/show/NCT04204447"
44,"NCT02959775","Immunogenicity of Hepatitis B Vaccination Among Drug Users",,"Completed","Has Results","Hepatitis B Vaccination","Biological: 60 µg dose hepatitis B vaccine|Biological: 20 µg dose hepatitis B vaccine","Number and Rate of Participants With Anti-HBs Seroconversion at Month 7|Anti-HBs Concentration at Month 7|Anti-HBs Concentration at Month 12|Number and Rate of Participants With Anti-HBs Seroconversion at Month 12|Occurrence of Adverse Events After Vaccination|Serious Adverse Events (SAE) Occurred During Month 12","Shanxi Medical University|Centers for Disease Control and Prevention, China","Male","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","480","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","2012ZX10002001003004002","August 2014","May 2015","October 2015","November 9, 2016","February 18, 2022","February 18, 2022",,,"https://ClinicalTrials.gov/show/NCT02959775"
45,"NCT00608192","HIV and Hepatitis Care Coordination in Methadone Treatment",,"Completed","No Results Available","Hepatitis, Viral, Human|HIV Infections","Behavioral: Testing, Education, & Counseling (TEC)|Behavioral: Hepatitis Care Coordination (HCC)","Vaccination adherence visits|Health Care Utilization Survey|Intervention Costs & Hepatitis Care Utilization: DATCAP, public and private health care system administrative databases|Hepatitis A Knowledge Test|Hepatitis B Knowledge Test|Hepatitis C Knowledge Test|HIV Knowledge Test|Risk Behavior Survey|Addiction Severity Index","University of California, San Francisco|National Institute on Drug Abuse (NIDA)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","489","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","R01DA020781","January 2008","June 2011","June 2011","February 6, 2008",,"January 16, 2013","San Francisco General Hospital Opiate Treatment Outpatient Program, San Francisco, California, United States|Beth Israel Medical Center Methadone Maintenance Program, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00608192"
46,"NCT03425513","Hepatitis B Virus Prevalence and Risk Factors in Belgium","HBVBE","Completed","No Results Available","Hepatitis B","Diagnostic Test: Hepatitis B serology|Other: Questionnaire","Seroprevalence of current HBV infection in the Middle Limburg population|Seroprevalence of past or current HBV infection in the Middle Limburg population|Assess risk factors for current HBV infection in the Middle Limburg population|Assess risk factors for past or current HBV infection in the Middle Limburg population","Hasselt University","All","18 Years to 70 Years   (Adult, Older Adult)",,"1131","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","HBVBE","May 12, 2017","November 27, 2017","November 27, 2017","February 7, 2018",,"January 27, 2020","Ziekenhuis Oost-Limburg, Genk, Limburg, Belgium",,"https://ClinicalTrials.gov/show/NCT03425513"
47,"NCT00473824","Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation",,"Terminated","Has Results","Sequelae of Viral Hepatitis|Transplantation Infection|Evidence of Liver Transplantation","Biological: Hepatitis C Immune Globulin Intravenous (Human) 5%","Post Transplant Reduction in Viral Load (as Measured Quantitatively by Hepatitis C Virus (HCV) Reverse Transcription-Polymerase Chain Reaction (HCV RT-PCR)).","ADMA Biologics, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","7","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Nabi-3104","May 2007","February 2009","February 2009","May 16, 2007","February 7, 2012","July 30, 2021","Mayo Clinic, Phoenix, Arizona, United States|Mayo Clinic, Jacksonville, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00473824"
48,"NCT02003703","Comparative Efficacy of an Intensified Re-vaccination Scheme for Hepatitis B Virus Infection Among Patients Infected With HIV .","CORE-HIV","Completed","No Results Available","Hepatitis B|HIV","Biological: Recombinant Hepatitis B Virus Vaccine","Serologic Response|Local Reactions to Vaccine|Systemic Reactions to the Vaccine","Universidad de Valparaiso|Roche Pharma AG|GlaxoSmithKline|Aclin Laboratory","All","18 Years and older   (Adult, Older Adult)","Phase 3","107","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","45/2012","May 2015","June 2018","December 2018","December 6, 2013",,"January 31, 2019","Hospital Gustavo Fricke, Viña del Mar, Valparaíso, Chile",,"https://ClinicalTrials.gov/show/NCT02003703"
49,"NCT01341808","Immunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients",,"Completed","No Results Available","Inflammatory Bowel Disease|Crohn's Disease|Ulcerative Colitis|Hepatitis A","Biological: Epaxal Berna (virosomal hepatitis A vaccine)","antibody titer to hepatitis A vaccine|vaccine-associated adverse events and side effects","Asan Medical Center","All","18 Years to 40 Years   (Adult)","Phase 4","493","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2011-0047","April 2011","February 2013","March 2013","April 26, 2011",,"March 19, 2013","Asan Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01341808"
50,"NCT02190305","Rapid Diagnostics for HIV and Hepatitis",,"Withdrawn","No Results Available","HIV Infections|Hepatitis B Infections|Hepatitis C Infections","Device: Multiplo HBc/HIV/HCV and Reveal HBsAg","Clinical performance of Reveal HBsAg and Multiplo HBc/HIV/HCV","MedMira Laboratories Inc.","All","13 Years and older   (Child, Adult, Older Adult)","Not Applicable","0","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MCP002","May 2014","August 2015","August 2015","July 15, 2014",,"April 21, 2023","Keck School of Medicine - LAUSC, Los Angeles, California, United States|SCFLD Hepatology Diagnostic Research Laboratory, Miami, Florida, United States|Minneapolis Medical Research Foundation, Minneapolis, Minnesota, United States|NYC Dept Health & Mental Hygiene, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02190305"
51,"NCT01405183","Association Between Hepatitis C Infection and Renal Cell Carcinoma",,"Completed","No Results Available","Hepatitis C|Renal Cell Carcinoma|Colorectal Cancer","Other: Hepatitis C testing","Prevalence of hepatitis C in renal cell carcinoma patients","Henry Ford Health System|Schering-Plough","All","18 Years and older   (Adult, Older Adult)",,"240","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","P08406","January 2011","August 2013","September 2013","July 29, 2011",,"September 17, 2014","Henry Ford Hospital, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01405183"
52,"NCT00139113","Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young Children",,"Completed","No Results Available","Hepatitis A","Biological: hepatitis A vaccine","concentration of antibody to hepatitis A virus|reported side effects and adverse events|antibodies to routine childhood vaccinations","Centers for Disease Control and Prevention|Alaska Native Medical Center|GlaxoSmithKline","All","up to 6 Months   (Child)","Phase 4","248","U.S. Fed|Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","CDC-NCID-1358|U50/CCU022279","September 1996","June 2001","June 2001","August 31, 2005",,"August 30, 2012","Anchorage Neighborhood Health Center, Anchorage, Alaska, United States|Alaska Native Medical Center, Anchorage, Alaska, United States",,"https://ClinicalTrials.gov/show/NCT00139113"
53,"NCT06058416","Immunogenicity and Safety of Hepatitis A Among People Aged 18-50 Years Old",,"Active, not recruiting","No Results Available","Hepatitis A","Biological: Healive (hepatitis A vacine(human diploid cell), inactivated)","The seroconversion rate of anti-HAV antibody 28 days after two dose of vaccination of hepatitis A vaccine with an interval of 6 month|Incidence of adverse reaction within 28 days after one dose of vaccination|The seroconversion rate of anti-HAV antibody 28 days after two dose of vaccination of hepatitis A vaccine with an interval of 18 month, 36 months, and 60 months|The seropositive rate, GMC and GMI of anti-HAV antibody 28 days after two dose of vaccination of hepatitis A vaccine with an interval of 6 months, 18 month, 36 months, and 60 months|The seropositive rate, GMC and GMI of anti-HAV antibody 28 days after one dose of vaccination of hepatitis A vaccine with an interval of 6 months, 18 month, 36 months, and 60 months|The seropositive rate, GMC and GMI of anti-HAV antibody 28 days after two dose of vaccination of hepatitis A vaccine with an interval of 6 months, 18 month, 36 months, and 60 months among people with underlying conditions|The seropositive rate of anti-HAV antibody before vaccination|Incidence of adverse reaction within 7 days after one dose of vaccination|Incidence of adverse reaction within 28 days after two dose of vaccination|Incidence of adverse reaction within 28 days after one dose of vaccination among different group of people","Sinovac Biotech Co., Ltd|Liaoning Center for Disease Control and Prevention","All","18 Years to 50 Years   (Adult)","Phase 4","1092","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PRO-HAV-MA4001-LN","October 24, 2023","March 17, 2024","December 31, 2029","September 28, 2023",,"November 28, 2023","Liaoning Center for Disease Control and Prevention, Shenyang, Liaoning, China",,"https://ClinicalTrials.gov/show/NCT06058416"
54,"NCT04456504","HepB-CpG Series for Healthcare Workers Who Are Hepatitis B Vaccine Nonresponders",,"Completed","No Results Available","Healthcare Worker, Hepatitis B Vaccine, Nonresponder","Biological: Recombinant hepatitis B vaccine with CpG adjuvant","Number of participants who failed to respond to 5 or more doses of hepatitis B vaccine with aluminum adjuvant who respond to hepatitis B vaccine with CpG adjuvant series|Number of participants who respond to a single dose of hepB-CpG|Proportion of participants who are nonresponders with each risk factor","University of Wisconsin, Madison","All","18 Years and older   (Adult, Older Adult)","Phase 4","47","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2020-0631|A561000|PHARM/PHARMACY|Protocol Version 6/11/2020","September 15, 2020","December 6, 2023","December 6, 2023","July 2, 2020",,"December 8, 2023","University of Wisconsin, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04456504"
55,"NCT02055365","Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers",,"Completed","Has Results","Hepatitis B","Biological: Hepatitis B Vaccine (Recombinant)","Number of Differentially Expressed Genes at p < 0.05 (Without Multiple Testing Correction).|Number of Significantly Differentially Expressed Genes at False Discovery Rate (FDR)< 0.05 (Upon Correction for Multiple Testing).","Rockefeller University","All","18 Years to 60 Years   (Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","BRO-0828","February 18, 2014","January 6, 2015","January 6, 2015","February 5, 2014","April 5, 2018","May 7, 2018","The Rockefeller University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02055365"
56,"NCT03405597","HBsAb Response After HBV Vaccination in Chronic Hepatitis B Patients Who Have Lost HBsAg",,"Unknown status","No Results Available","Chronic Hepatitis B, HBsAg, Hepatitis B Vaccine","Drug: Commercial Hepatitis B vaccine|Other: Standard Treatment","HBsAb level at 4 weeks after complete vaccine injection|HBsAb level at 6 months after complete vaccine injection|Adverse event from HBV vaccine|Factors associated with HBV vaccine response","Mahidol University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","97","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13/2560(EC1)","March 30, 2017","February 28, 2018","June 30, 2018","January 23, 2018",,"January 23, 2018","Faculty of Medicine Siriraj Hospital, Bangkoknoi, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT03405597"
57,"NCT04970836","The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort","IRHBRVD","Recruiting","No Results Available","Hepatitis B|Vaccination; Infection|Preventable Disease, Vaccine","Biological: recombinant hepatitis B vaccine","anti-HBs titer response rate at 7-10 days|anti-HBs titer response rate at one month|anti-HBs titer response rate at 6 months|anti-HBs titer response rate at 12 months|anti-HBs titer immune response change at 12 months","National Taiwan University Hospital|Academia Sinica, Taiwan|Ministry of Science and Technology, Taiwan","All","20 Years to 36 Years   (Adult)","Not Applicable","240","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","202012221MINB|110-2314-B-002-132","August 1, 2021","July 31, 2024","December 31, 2024","July 21, 2021",,"June 27, 2022","Family Medicine, NTUH, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT04970836"
58,"NCT02555475","The Prime Study - Comparing Hepatitis C Care and Treatment in a Primary Health Care Service With a Tertiary Hospital",,"Completed","No Results Available","Hepatitis C","Other: community based hepatitis C care and treatment","To measure the proportion of people attending at a Primary Health Care Service for their genotype 1 HCV infection who commence antiviral treatment (Viekira Pak and ribavirin) and have a SVR 12.|To measure the proportion of people attending a PHCS with G1 HCV infection who commence antiviral treatment (Viekira Pak and ribavirin) if they are managed at a PHCS compared to those who are referred to and managed at a tertiary hospital.|To measure the proportion of people with G1 HCV who have an SVR12 at a PHCS compared a tertiary hospital.|To measure the reduction in HCV viraemia (community viral load) among participants considering retention through the cascade of care and SVR12.|To measure the cost effectiveness of managing and treating people in a primary health service compared to a tertiary hospital.|To define the cascade of care for patients referred to a community hepatitis nurse for assessment of HCV.","Macfarlane Burnet Institute for Medical Research and Public Health Ltd|St Vincent's Hospital Melbourne","All","18 Years and older   (Adult, Older Adult)","Not Applicable","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HREC/15/SVHM/41","March 2016","December 22, 2017","May 22, 2018","September 21, 2015",,"May 24, 2018","St Vincents Hospital Melbourne, Melbourne, Victoria, Australia|Burnet Institute, Melbourne, Victoria, Australia|Hospital Liver Clinic, Greenlane, Auckland, New Zealand|Auckland Opioid Treatment Service (AOTS), Pt Chevalier, Auckland, New Zealand|Hepatitis C Community Clinic, Sydenham, Christchurch, New Zealand|Calder Centre Auckland, Auckland, New Zealand|Auckland Central liver Clinic, Auckland, New Zealand|Community Alcohol and Drug Services, Auckland, New Zealand",,"https://ClinicalTrials.gov/show/NCT02555475"
59,"NCT03038802","A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection","HBV003","Not yet recruiting","No Results Available","Chronic Hepatitis b","Biological: Therapeutic hepatitis B vaccine|Biological: Commercial Hepatitis B vaccine","Safety assessment: Frequency of vaccine-related adverse events relative to active comparator vaccine|Viral load|Seroconversion|T-cell response|B cell response","Vaxine Pty Ltd|Australian Respiratory and Sleep Medicine Institute","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","40","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HBV003","September 2023","December 2025","December 2025","February 1, 2017",,"March 31, 2023","ARASMI, Adelaide, South Australia, Australia",,"https://ClinicalTrials.gov/show/NCT03038802"
60,"NCT05526820","A Study of Combined Immunization With Live Attenuated Varicella Vaccine and Inactivated Hepatitis A Vaccine",,"Completed","No Results Available","Varicella","Biological: The live attenuated varicella vaccine and the inactivated hepatitis A vaccine","Seroconversion rates of the varicella antibody|Seroconversion rates of anti-HAV antibody|Seropositive rates of varicella antibody|GMT of varicella antibody|GMI of varicella antibody|Seropositive rates of anti-HAV antibody|GMC of anti-HAV antibody|GMI of anti-HAV antibody|The incidence of adverse events|The incidence of local and systemic solicitation adverse reactions|The incidence of serious adverse events (SAE)","Sinovac (Dalian) Vaccine Technology Co., Ltd.","All","12 Months to 15 Months   (Child)","Phase 4","450","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PRO-VZV-4001","April 8, 2021","April 8, 2021","February 27, 2022","September 2, 2022",,"September 2, 2022","Feicheng Center for Disease Control and Prevention, Tai'an, Shandong, China",,"https://ClinicalTrials.gov/show/NCT05526820"
61,"NCT06184230","Persistence of Hepatitis A Antibody in Healthy Adults ~32 Years Post Vaccination.",,"Not yet recruiting","No Results Available","Hepatitis A","Biological: Hepatitis A Vaccine","Persistence of Antibody","Best Healthcare Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 4","300","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Study 023-Persistence","January 2024","March 2025","June 2025","December 28, 2023",,"December 28, 2023",,"""Study Protocol and Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/30/NCT06184230/Prot_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT06184230"
62,"NCT03365921","A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Lot Consistency Trial)",,"Completed","No Results Available","Hepatitis E","Biological: Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.","Seroconversion rate and GMC of anti-HEV IgG at Month 7.|Adverse reactions/events of all subjects","Xiamen Innovax Biotech Co., Ltd|Jiangsu Province Centers for Disease Control and Prevention","All","18 Years to 50 Years   (Adult)","Phase 4","360","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","PRO-HE-010","October 27, 2018","June 16, 2019","June 16, 2019","December 7, 2017",,"May 7, 2020","Dongtai City Center for Disease Control and Prevention, Dongtai, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT03365921"
63,"NCT01203319","The Immunogenicity and Safety of 60mcg/30mcg Recombinant Hepatitis B Vaccines in People Who Failed to Respond to Routine Administration of Hepatitis B Vaccines",,"Completed","Has Results","Hepatitis b","Biological: 60mcg/1.0ml recombinant hepatitis B vaccine|Biological: 30mcg/1.0ml recombinant hepatitis B vaccine|Biological: 10mcg/1.0ml recombinant hepatitis B vaccine","Immunogenicity of Recombinant Hepatitis B Vaccines in Nonresponders|the Safety of Recombinant Hepatitis B Vaccines in Nonresponders","Jiangsu Province Centers for Disease Control and Prevention|Shenzhen Kangtai Biological Products Co., LTD","All","16 Years and older   (Child, Adult, Older Adult)","Phase 2|Phase 3","1091","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","KT0003","November 2006","December 2010","March 2011","September 16, 2010","April 23, 2012","April 27, 2012",,,"https://ClinicalTrials.gov/show/NCT01203319"
64,"NCT02057263","The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults",,"Completed","No Results Available","Hepatitis B","Drug: Alendronate|Drug: Hepatitis B Vaccine|Drug: Placebo","Safety/Adverse events|Efficacy","Massachusetts General Hospital","All","40 Years to 70 Years   (Adult, Older Adult)","Phase 1","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2014-P-000040","April 2014","February 2016","February 2016","February 7, 2014",,"October 21, 2016","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02057263"
65,"NCT00739128","Response to Hepatitis B Vaccine in Celiac Disease Patients",,"Terminated","No Results Available","Celiac Disease","Biological: hepatitis B vaccine (EngerixB)","1. The primary endpoint of the study will be comparison of the geometric mean titers of anti-HBs between the intradermal and the intramuscular groups.|1. Rate of responders four weeks after the completion of the series 2. Rate and characteristics of adverse drug reactions 3. Numerical increase in the antibodies titer before and after vaccination 4. Rate of responders in the cross over phase","Shaare Zedek Medical Center","All","1 Year and older   (Child, Adult, Older Adult)","Not Applicable","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15363.ct.il","February 2009","March 2011","March 2011","August 21, 2008",,"April 15, 2011","SZMC, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT00739128"
66,"NCT03919578","Protectivity and Safety Following Recombinant Hepatitis B Vaccine",,"Completed","No Results Available","Immunogenicity","Biological: Recombinant Hepatitis B vaccine|Biological: Recombinant Hepatitis B (Bio Farma)","Percentage of subjects with increasing antibody titer >= 4 times|Geometric Mean Titer (GMT)|Percentage of subjects with transition of seronegative to seropositive|Percentage of subjects with at least one immediate reaction|Percentage of subjects with at least one of these adverse events|Serious adverse event after vaccination|Comparison adverse events between Investigational Products (Hepatitis B) and Control|Comparison of adverse events between each lot number of Recombinant Hepatitis B vaccine","PT Bio Farma","All","10 Years to 40 Years   (Child, Adult)","Phase 2|Phase 3","536","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Hep B 0218","September 11, 2019","January 30, 2020","February 28, 2020","April 18, 2019",,"September 19, 2022","RSND, Semarang, Central Java, Indonesia",,"https://ClinicalTrials.gov/show/NCT03919578"
67,"NCT04029454","Neovac 2 Burkina Faso: Impact of the Integration of Hepatitis B Birth Dose Vaccine Into the Infant Immunization Schedule","NEOVAC2BK","Completed","No Results Available","Hepatitis B","Biological: birth dose vaccination against hepatitis B strategy","Proportion of positive HBV infection in 9-month-old children vaccinated at birth compared to children receiving their first vaccination at 8 weeks.|Prevalence rate of HBV infection in pregnancy from HBsAg and HBeAg profiles in mothers of 9-month-old children|Sensibility and specificity of low-cost alternative HBV markers","Institut Pasteur|Agence de Médecine Préventive, France|Centre Muraz|Institut National de la Santé Et de la Recherche Médicale, France|Gilead Sciences|Abbott","Female","15 Years to 55 Years   (Child, Adult)","Not Applicable","10000","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2017-083","October 19, 2020","August 31, 2023","December 15, 2023","July 23, 2019",,"December 19, 2023","District sanitaire de Dafra, Bobo-Dioulasso, Dafra, Burkina Faso|District sanitaire de Do, Bobo-Dioulasso, Do, Burkina Faso",,"https://ClinicalTrials.gov/show/NCT04029454"
68,"NCT03456037","Incidence Of Hepatitis In Intensive Care Unit",,"Unknown status","No Results Available","Intensive Care Unit","Other: hepatitis viruses","HBsAg|anti-HCV","Sakarya University","All","18 Years to 120 Years   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","hepatitis","April 1, 2018","May 1, 2019","July 1, 2019","March 7, 2018",,"March 7, 2018","Sakarya University Research and Training Hospital, Sakarya, Turkey",,"https://ClinicalTrials.gov/show/NCT03456037"
69,"NCT01926860","PCV13 + Hepatitis A Vaccine for Adults","PCV13+HepA","Unknown status","No Results Available","Measurement of Immune Response to Prevenar13|Measurement of Immune Response to Hepatitis A","Biological: Prevenar13|Biological: Hepatitis A vaccine","Immune response to PCV13|Immune response to Hep A vaccine","Helsinki University Central Hospital","All","50 Years and older   (Adult, Older Adult)","Phase 4","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PCV13 adults + Hep A","September 2013","September 2014","September 2015","August 21, 2013",,"August 21, 2013","Aava Medical Centre, Helsinki, Finland|Department of Infectious Diseases, Eskilstuna, Sweden",,"https://ClinicalTrials.gov/show/NCT01926860"
70,"NCT04470271","Re-linkage to Care of Patients With Hepatitis C",,"Unknown status","No Results Available","Viral Hepatitis C","Other: Patients with hepatitis C lost follow up","Number of participants who were lost of follow up","Austral University, Argentina","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","CIE N° P 20-008","September 1, 2020","December 31, 2020","March 31, 2021","July 14, 2020",,"July 14, 2020","Universidad Austral, Pilar, Buenos Aires, Argentina",,"https://ClinicalTrials.gov/show/NCT04470271"
71,"NCT05099757","The Immunogenicity and Persistence of Booster Dose With Hepatitis B Vaccine in College Students",,"Unknown status","No Results Available","Hepatitis B Vaccine","Biological: 20 µg dose hepatitis B vaccine","Anti-HBs Seroconversion Rate at Months 1|Anti-HBs Seroconversion Rate at Months 3|Anti-HBs Seroconversion Rate at Months 7|Anti-HBs Seroconversion Rate at Months 12|Anti-HBs Seroconversion Rate at Months 18|Anti-HBs Seroconversion Rate at Months 24|Anti-HBs Seroconversion Rate at Months 30|Anti-HBs Concentration at Months 1|Anti-HBs Concentration at Months 3|Anti-HBs Concentration at Months 7|Anti-HBs Concentration at Months 12|Anti-HBs Concentration at Months 18|Anti-HBs Concentration at Months 24|Anti-HBs Concentration at Months 30","Shanxi Medical University","All","18 Years and older   (Adult, Older Adult)","Phase 4","150","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","DXSHB20211012","February 20, 2022","November 25, 2022","December 15, 2023","October 29, 2021",,"December 6, 2021",,,"https://ClinicalTrials.gov/show/NCT05099757"
72,"NCT03083158","Immunity to Hepatitis B Vaccine","HVP01","Completed","No Results Available","Hepatitis B|Immunization; Infection","Drug: Hepatitis B vaccine","Antibody response to the first dose of hepatitis B vaccine|Kinetics of the immune response to the first dose of hepatitis B vaccine with respect to cellular immune response|Kinetics of the immune response to the first dose of hepatitis B vaccine with respect to transcriptomic response|Kinetics of the immune response to the first dose of hepatitis B vaccine with respect to proteomic response|Kinetics of the immune response to the first dose of hepatitis B vaccine with respect to metabalomic response|Kinetics of the immune response to the first dose of hepatitis B vaccine with respect to epigenetic response|Kinetics of the immune response to the first dose of hepatitis B vaccine with respect to lymph node response|Identify the DNA sequence of B- and T- cell receptors following vaccination","University of British Columbia|Vanderbilt University|J. Craig Venter Institute|The Scripps Research Institute|University of California, San Diego|Institut Pasteur|Human Vaccines Project","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 4","16","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","H17-00175","March 6, 2017","February 1, 2018","February 1, 2018","March 17, 2017",,"November 25, 2020","Vaccine Evaluation Center, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT03083158"
73,"NCT05710120","Hepatitis C Screening Alerts",,"Completed","No Results Available","Hepatitis C","Other: Hepatitis C Screening Alerts in CHORUS™|Other: Standard of Care","Screening to Diagnosis Ratio for Hepatitis C Infection|Screening Tests for Hepatitis C Infection|HCV RNA Viral Load Tests|HCV Screening History","Epividian|Gilead Sciences|ZS|AIDS Healthcare Foundation","All","18 Years and older   (Adult, Older Adult)",,"125706","Industry|Other","Observational","Observational Model: Other|Time Perspective: Other","COL2023-002","January 16, 2023","October 17, 2023","October 17, 2023","February 2, 2023",,"February 16, 2024","AIDS Healthcare Foundation, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT05710120"
74,"NCT05902624","Efficacy and Safety of Hepatitis B Virus Vaccine(HBV) in Treatment of Cutaneous Warts",,"Not yet recruiting","No Results Available","Cutaneous Warts","Drug: Hepatitis B Virus Vaccine(HBV)","Effectiveness of Hepatitis B virus vaccine(HBV) in treatment of cutaneous warts .","Assiut University","All","10 Years and older   (Child, Adult, Older Adult)","Early Phase 1","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","cutaneous warts treatment","June 10, 2023","May 20, 2024","August 20, 2024","June 15, 2023",,"June 15, 2023",,,"https://ClinicalTrials.gov/show/NCT05902624"
75,"NCT02994537","Study of the Clinical Features of Autoimmune Hepatitis",,"Recruiting","No Results Available","Hepatitis, Autoimmune","Other: Different biochemical results or pathogenesis.","Biochemical remission of participants","Li Yang|West China Hospital","All","18 Years to 80 Years   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AAIH-001","October 2013","June 1, 2022","December 31, 2022","December 16, 2016",,"April 29, 2022","Division of Gastroenterology & Hepatology,West China Hospital,Sichuan University, Chengdu, Sichuan, China",,"https://ClinicalTrials.gov/show/NCT02994537"
76,"NCT02445703","Comparison of Immunization Schedules of Inactivated Hepatitis A Vaccine and Combined Hepatitis A and Hepatitis B Vaccine",,"Completed","No Results Available","Hepatitis A|Hepatitis B","Biological: Inactivated Hepatitis A vaccine (HAV)|Biological: Combined hepatitis A and hepatitis B vaccine (HABV)","The Post-immunization Seropositivity Rates (SPR) to Hepatitis A|The Post-immunization Geometric Mean Concentration (GMC) of Hepatitis A Antibody (anti-HAV)|The Post-immunization GMC of Hepatitis B Surface Antibody (HBsAb)|The Post-immunization SPR to Hepatitis B|Occurrence of Adverse Events (AEs)","Sinovac Biotech Co., Ltd","All","18 Months to 24 Months   (Child)","Phase 4","301","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","PRO-HAB-4005","May 2014","January 2015","June 2016","May 15, 2015",,"July 27, 2021","Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, China",,"https://ClinicalTrials.gov/show/NCT02445703"
77,"NCT00383591","Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years",,"Completed","No Results Available","Hepatitis B","Biological: Hepatitis B adjuvanted vaccine|Biological: Engerix-B","Anti-HBs seroprotection|Response to booster|Solicited, unsolicited symptoms and serious adverse events","GlaxoSmithKline","All","15 Years and older   (Child, Adult, Older Adult)","Phase 3","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","208129/047","March 2002",,"January 2004","October 3, 2006",,"March 23, 2017","GSK Investigational Site, Hradec Kralove, Czech Republic|GSK Investigational Site, Bandar Tun Razak, Cheras, Malaysia|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Malaga, Spain",,"https://ClinicalTrials.gov/show/NCT00383591"
78,"NCT01564134","Dose of Hepatitis B Vaccines in Non/Low-response Populations",,"Completed","No Results Available","Vaccination; Complications, Reaction, Serum","Biological: hepatitis B vaccine","Seroconversion rates of different doses of vaccines the levels of HBs-Ab after vaccination","Wu Jiang|Beijing Municipal Science & Technology Commission|Centers for Disease Control and Prevention, China","All","1 Year to 65 Years   (Child, Adult, Older Adult)","Not Applicable","537","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","BJCDCWJ201102","August 2011","March 2012","June 2012","March 27, 2012",,"July 10, 2013","Xicheng Centers For Disease Prevention & Control, Xicheng District, Beijing, China|Chifeng Centers For Disease Prevention & Control, Chifeng, Inner Mongolia, China",,"https://ClinicalTrials.gov/show/NCT01564134"
79,"NCT05725109","Hepatitis C Diagnosis to Treatment Management",,"Completed","No Results Available","Hepatitis C","Other: Hepatitis C Treatment Alerts in CHORUS™|Other: Standard of Care","Prescriptions for HCV treatment|HCV RNA viral load tests","Epividian|Gilead Sciences|AIDS Healthcare Foundation","All","18 Years and older   (Adult, Older Adult)",,"1063","Industry|Other","Observational","Observational Model: Other|Time Perspective: Other","COL2023-001","January 16, 2023","October 17, 2023","October 17, 2023","February 13, 2023",,"February 16, 2024","AIDS Healthcare Foundation, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT05725109"
80,"NCT06203925","Hepatitis C Virus Self-testing (HCVST) in Sexual and Gender Minorities in Rio de Janeiro",,"Not yet recruiting","No Results Available","Hepatitis C","Diagnostic Test: Hepatitis C virus self-test (oral fluid HCVST)|Diagnostic Test: Hepatitis C virus self-test (blood-based HCVST)","Number of SGM living in Rio de Janeiro (Brazil) who requested an HCVST kit through a web-based platform|Number of SGM living in Rio de Janeiro (Brazil) who received and performed the test.|Proportion of MSM/TGW who correctly performed HCVST with oral-fluid and blood-based kits without assistance of a healthcare worker|Socio-demographic characteristics through the data obtained from the study.|Type-preference test through the data obtained from the study.|Participants who reported Easy test.|Possible outcomes through the data obtained from the study.|Participants through the data obtained from the study.|Participants who attending a consultation through the data obtained from the study.|Prevalence of reactive HCV through the data obtained from the study.|Cost per identification through the data obtained from the study.|Particiopants who used telehealth through the data obtained from the study.|Socio-demographic characteristics of MSM/TGW through the data obtained from the study.|Participants who report the test through the data obtained from the study.|Participants who needed help from a healthcare.|Preference for tests|Easy test|Participants who needed a consultation.|Positive participants|Cost for using the test|Positive participants with HCV-RNA","Oswaldo Cruz Foundation|World Health Organization|UNITAID","All","18 Years to 99 Years   (Adult, Older Adult)",,"3000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","69747223.4.0000.5262","January 8, 2024","December 31, 2025","December 31, 2025","January 12, 2024",,"January 12, 2024","Evandro Chagas National Institute of Infectious Diseases, Rio de Janeiro, Rio De Janeiro/RJ, Brazil",,"https://ClinicalTrials.gov/show/NCT06203925"
81,"NCT05482282","Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma)",,"Not yet recruiting","No Results Available","Diphtheria Vaccine Adverse Reaction|Tetanus Vaccine Adverse Reaction|Pertussis Vaccine Adverse Reaction|Haemophilus Influenzae Type B Vaccine Adverse Reaction|Hepatitis B Vaccine Adverse Reaction","Biological: Recombinant Hepatitis B new Bulk vaccine|Biological: DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine|Biological: Recombinant Hepatitis B vaccine (Registered BioFarma)|Biological: Pentabio","To evaluate protectivity of DTP-HB-Hib Vaccine (Bio Farma) using new Hepatitis B bulk (Bio Farma)|To asses the local and systemic reactions within 30 minutes|To asses the local and systemic reactions within 30 minutes to 7 days after immunization|To asses the local and systemic reactions within 7 days to 28 days after immunization|To asses the serious adverse event","PT Bio Farma|Hasan Sadikin General Hospital","All","1 Day to 3 Days   (Child)","Phase 3","220","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Penta BS22","October 2022","December 2022","February 2023","August 1, 2022",,"August 1, 2022","Garuda Primary Health Centre, Bandung, West Java, Indonesia|Ibrahim Adjie Primary Health Centre, Bandung, West Java, Indonesia|Puter Primary Health Centre, Bandung, West Java, Indonesia",,"https://ClinicalTrials.gov/show/NCT05482282"
82,"NCT03330171","Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine","MV/VV/Hep-AV","Unknown status","No Results Available","Measles|Varicella|Hepatitis A","Biological: Measles vaccine|Biological: Hepatitis-A vaccine|Biological: Varicella vaccine","Number of participants with seroprotective antibody titres (IgG ≥330 mIU/ml quantified by ELISA) one month post booster measles vaccination|Number of participants with seroprotective antibody titres (IgG ≥300 mIU/ml quantified by ELISA) one month post varicella vaccination|Number of participants with seroprotective antibody titres (IgG ≥20 mIU/ml quantified by ELISA) one month post hepatitis-A vaccination|Number of participants with vaccine-related adverse events after primary measles vaccination|Number of participants with vaccine-related adverse events after booster measles vaccination|Number of participants with vaccine-related adverse events after varicella vaccination|Number of participants with vaccine-related adverse events after hepatitis-A vaccination|Persistence of immunogenicity","University of Witwatersrand, South Africa","All","18 Weeks to 19 Months   (Child)","Phase 4","278","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","MV/VV/Hep-AV","April 10, 2017","February 26, 2019","December 1, 2022","November 6, 2017",,"March 17, 2020","Chris Hani Baragwanath Academic Hospital; Nrf/Dst Vpd Rmpru, Soweto, Gauteng, South Africa",,"https://ClinicalTrials.gov/show/NCT03330171"
83,"NCT02601040","Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines",,"Completed","No Results Available","Hepatitis A","Biological: Attenuated Hepatitis A Vaccine, H2 Strain|Biological: Inactivated Hepatitis A Vaccine, Lu8 Strain|Biological: Group A Meningococcal Polysaccharide vaccine","Changes of hepatitis A antibody concentration|Incidence of adverse events","Jiangsu Province Centers for Disease Control and Prevention|Institute of Medical Biology, Chinese Academy of Medical Sciences","All","18 Months to 65 Years   (Child, Adult, Older Adult)","Phase 4","13500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","JSEPI-004","November 2011","June 2014","October 2015","November 10, 2015",,"November 10, 2015","Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China|Institute of Medical Biology -Chinese Academy of Medical Sciences, Kunming, Yunnan, China",,"https://ClinicalTrials.gov/show/NCT02601040"
84,"NCT06191471","Hepatitis A Virus Induced Acute Acalculous Cholecystitis Diagnosed Postoperatively: Case Report",,"Completed","No Results Available","Acute Acalculous Cholecystitis","Other: Laparoscopic cholecystectomy for hepatitis A induced acute acalculous cholecystitis","Hepatitis A induced acute acalculous cholecystitis","University of Balamand","Female","18 Years to 90 Years   (Adult, Older Adult)",,"1","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","UBalamandAAC","November 1, 2023","December 10, 2023","December 10, 2023","January 5, 2024",,"January 5, 2024","University Of balamand, Beirut, Lebanon",,"https://ClinicalTrials.gov/show/NCT06191471"
85,"NCT04177043","Model Towards Elimination of Hepatitis C Infection in Egypt: Feasibility and Effectiveness in 73 Villages",,"Completed","No Results Available","Hepatitis C, Chronic","Diagnostic Test: HCV antibody and hepatitis B surface antigen (HBsAg) rapid diagnostic tests|Drug: DAAs","incidince of HCV in population","Egyptian Liver Hospital","All","12 Years and older   (Child, Adult, Older Adult)","Phase 4","221855","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","village2015","June 2015","June 2018","December 2018","November 26, 2019",,"November 26, 2019",,,"https://ClinicalTrials.gov/show/NCT04177043"
86,"NCT00356564","Persistence of the Immune Response to Hepatitis B in 7-9 Years Old Children Previously Vaccinated With DTPa-HBV-IPV/Hib",,"Completed","No Results Available","Hepatitis B","Biological: hepatitis B vaccine","Anti-HBs antibody concentration|Persistence of antibodies to the other DTPa-HBV-IPV/Hib vaccine antigens.|Sol & unsol symptoms after HBV vaccination, SAEs","GlaxoSmithKline","All","7 Years to 9 Years   (Child)","Phase 4","350","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","106744","July 2006",,"December 2006","July 26, 2006",,"October 12, 2016","GSK Investigational Site, Ettenheim, Baden-Wuerttemberg, Germany|GSK Investigational Site, Kehl, Baden-Wuerttemberg, Germany|GSK Investigational Site, Oberkirch, Baden-Wuerttemberg, Germany|GSK Investigational Site, Offenburg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Aichach, Bayern, Germany|GSK Investigational Site, Bobingen, Bayern, Germany|GSK Investigational Site, Erding, Bayern, Germany|GSK Investigational Site, Kaufering, Bayern, Germany|GSK Investigational Site, Kempten, Bayern, Germany|GSK Investigational Site, Landsberg, Bayern, Germany|GSK Investigational Site, Lohr, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Noerdlingen, Bayern, Germany|GSK Investigational Site, Pegnitz, Bayern, Germany|GSK Investigational Site, Tutzing, Bayern, Germany|GSK Investigational Site, Weilheim, Bayern, Germany|GSK Investigational Site, Marburg/Lahn, Hessen, Germany|GSK Investigational Site, Salzgitter, Niedersachsen, Germany|GSK Investigational Site, Erkrath, Nordrhein-Westfalen, Germany|GSK Investigational Site, Krefeld, Nordrhein-Westfalen, Germany|GSK Investigational Site, Willich, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bad Sobernheim, Rheinland-Pfalz, Germany|GSK Investigational Site, Mainz, Rheinland-Pfalz, Germany|GSK Investigational Site, Schoeneberg - Kuebelberg, Rheinland-Pfalz, Germany|GSK Investigational Site, Trier, Rheinland-Pfalz, Germany|GSK Investigational Site, Bischofswerda, Sachsen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Altenholz, Schleswig-Holstein, Germany|GSK Investigational Site, Bredstedt, Schleswig-Holstein, Germany|GSK Investigational Site, Flensburg, Schleswig-Holstein, Germany|GSK Investigational Site, Flensburg, Schleswig-Holstein, Germany|GSK Investigational Site, Husum, Schleswig-Holstein, Germany|GSK Investigational Site, Kiel, Schleswig-Holstein, Germany|GSK Investigational Site, Niebuell, Schleswig-Holstein, Germany|GSK Investigational Site, Lobenstein, Thueringen, Germany|GSK Investigational Site, Rudolstadt, Thueringen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT00356564"
87,"NCT00335881","Persistence of the Immune Response to Hepatitis B in 4-6 Years Old Children Previously Vaccinated With DTPa-HBV-IPV/Hib",,"Completed","No Results Available","Hepatitis B","Biological: hepatitis B vaccine","Anti-HBs antibody concentration|Persistence of antibodies to the other DTPa-HBV-IPV/Hib vaccine antigens.|Sol & unsol symptoms after HBV vaccination, SAEs","GlaxoSmithKline","All","4 Years to 6 Years   (Child)","Phase 4","300","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","106745","June 2006",,"November 2006","June 12, 2006",,"October 7, 2016","GSK Investigational Site, Bad Saulgau, Baden-Wuerttemberg, Germany|GSK Investigational Site, Boennigheim, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ettenheim, Baden-Wuerttemberg, Germany|GSK Investigational Site, Kehl, Baden-Wuerttemberg, Germany|GSK Investigational Site, Oberkirch, Baden-Wuerttemberg, Germany|GSK Investigational Site, Offenburg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Schwaebisch-Hall, Baden-Wuerttemberg, Germany|GSK Investigational Site, Stuttgart, Baden-Wuerttemberg, Germany|GSK Investigational Site, Tuttlingen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Cham, Bayern, Germany|GSK Investigational Site, Freising, Bayern, Germany|GSK Investigational Site, Kaufering, Bayern, Germany|GSK Investigational Site, Landsberg, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Noerdlingen, Bayern, Germany|GSK Investigational Site, Tutzing, Bayern, Germany|GSK Investigational Site, Weilheim, Bayern, Germany|GSK Investigational Site, Waren, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Salzgitter, Niedersachsen, Germany|GSK Investigational Site, Erkrath, Nordrhein-Westfalen, Germany|GSK Investigational Site, Heiligenhaus, Nordrhein-Westfalen, Germany|GSK Investigational Site, Kleve-Materborn, Nordrhein-Westfalen, Germany|GSK Investigational Site, Krefeld, Nordrhein-Westfalen, Germany|GSK Investigational Site, Willich, Nordrhein-Westfalen, Germany|GSK Investigational Site, Schoeneberg - Kuebelberg, Rheinland-Pfalz, Germany|GSK Investigational Site, Trier, Rheinland-Pfalz, Germany|GSK Investigational Site, Trier, Rheinland-Pfalz, Germany|GSK Investigational Site, Altenholz, Schleswig-Holstein, Germany|GSK Investigational Site, Bredstedt, Schleswig-Holstein, Germany|GSK Investigational Site, Flensburg, Schleswig-Holstein, Germany|GSK Investigational Site, Flensburg, Schleswig-Holstein, Germany|GSK Investigational Site, Flensburg, Schleswig-Holstein, Germany|GSK Investigational Site, Husum, Schleswig-Holstein, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00335881"
88,"NCT01421212","Pilot Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin (Boca HBVIg) Used in Combination With Lamivudine for Patients With Hepatitis B Virus (HBV) Associated Liver Disease Undergoing Liver Transplantation",,"Completed","No Results Available","Hepatitis B Virus Associated Liver Disease","Biological: Hepatitis B Immune Globulin (Boca HBVIg)","Number of hepatitis B virus positive liver transplant recipients with no hepatitis B virus recurrence after liver transplantation.|Number of participants who maintain a protective trough titer of anti hepatitis B antibodies beginning at 12 weeks post liver transplantation.|Change in anti hepatitis B antibodies levels with administration of Boca hepatitis B immune globulin concomitantly with Lamivudine.","Biotest Pharmaceuticals Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Nabi-4204","November 1999","February 2002","February 2002","August 22, 2011",,"January 22, 2019","University of California, San Francisco, San Francisco, California, United States|University of Florida, Gainesville, Florida, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Jackson Memorial Hospital / University of Miami, Miami, Florida, United States|Rush-Presbyterian - St. Luke's Medical Center, Chicago, Illinois, United States|The University of Michigan Health System, Ann Arbor, Michigan, United States|Rochester Methodist Hospital, Rochester, Minnesota, United States|Mount Sinai Medical Center, New York, New York, United States|New York-Presbyterian Hospital Columbia-Presbyterian Medical Center, New York, New York, United States|The University of North Carolina Hospitals, Chapel Hill, North Carolina, United States|Medical College of Virginia Commenwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01421212"
89,"NCT02809885","Hepatitis E Virus Infection in Pediatric Transplantation, a Prevalence Study","HEV","Unknown status","No Results Available","Transplantation","Biological: Hepatitis E serology","Hepatitis E virus prevalence in pediatric transplanted patients|Correlation between HEV prevalence and the different types of transplantation","Hospices Civils de Lyon","All","up to 18 Years   (Child, Adult)","Not Applicable","226","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","2013-810","December 19, 2013","December 19, 2017","December 19, 2017","June 22, 2016",,"August 9, 2017","Hospices Civils de Lyon, Bron, France",,"https://ClinicalTrials.gov/show/NCT02809885"
90,"NCT04870021","Hepatitis B Birth Dose for Newborns","HepB-BirD","Completed","No Results Available","Hepatitis B|Immunization; Infection","Biological: recombinant hepatitis B vaccine ENGERIX 10 micrograms (µ gm),|Behavioral: Short text messages and calls to parents for compliance to routine immunization schedule","Sero-proetction Level|Adverse event","Quaid-e-Azam University|Medical Research Council, Pakistan|Health Services Academy, Islamabad, Pakistan","All","12 Hours to 8 Months   (Child)","Phase 4","218","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","F.No.3-107/2013-IERC/HSA","March 15, 2015","November 30, 2015","June 30, 2016","May 3, 2021",,"May 3, 2021","Countess Dufferin Fund (CDF) Hospital, Hyderabad, Pakistan",,"https://ClinicalTrials.gov/show/NCT04870021"
91,"NCT04459897","Lyon Granulomatous Hepatitis Study","LGH","Unknown status","No Results Available","Patient Diagnosed or Treated for Granulomatous Hepatitis Followed in the Internal Medicine (and or) Hepato-gastroenterology Departments","Other: Evaluation of epithelioid and gigantocellular granulomas within the hepatic parenchyma by histopathology approach.","Evaluation of epithelioid and gigantocellular granulomas within the hepatic parenchyma by histopathology approach.","Hospices Civils de Lyon","All","18 Years and older   (Adult, Older Adult)",,"600","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","LGH_2020","January 1, 2019","January 1, 2023","January 1, 2023","July 7, 2020",,"July 7, 2020",": Hôpital de la Croix Rousse / GHN / service de médecine interne, Lyon, France|Hôpital Edouard Herriot / service de médecine interne, Lyon, France|Hôpital Lyon Sud / service de médecine interne, Pierre Bénite, France",,"https://ClinicalTrials.gov/show/NCT04459897"
92,"NCT00800787","Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Post Liver Transplantation","Nabi-HB-SC","Withdrawn","No Results Available","Hepatitis B, Chronic","Biological: Nabi-HB","To evaluate the efficacy of Nabi-HB administered subcutaneously weekly for a total of 14 weeks in patients who previously underwent a liver transplant. Levels will provide evidence if effective anti-HB levels >150 IU/ML can be maintained.|To evaluate the safety of Nabi-HB administered subcutaneously weekly for a total of 14 weeks.","Biotest Pharmaceuticals Corporation","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","0","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","4210","April 2010","August 2010","September 2010","December 2, 2008",,"January 18, 2016",,,"https://ClinicalTrials.gov/show/NCT00800787"
93,"NCT02605538","Hepatitis B in Cystic Fibrosis and Latent Tuberculosis Respectively",,"Withdrawn","No Results Available","Cystic Fibrosis|Hepatitis A|Hepatitis B|Tuberculosis","Biological: Vaccination with vaccine against hepatitis A and B","Positive antibody response to vaccination with Twinrix(TM) in CF patients compared to healthy volunteers","Karolinska University Hospital|Karolinska Institutet","All","1 Year and older   (Child, Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2012/251-31/2","September 1, 2015","December 2023","December 31, 2025","November 16, 2015",,"March 18, 2024","Stockholm CF Center, KArolinska University Hospital, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT02605538"
94,"NCT00456625","Immune Response to Hepatitis B Vaccine Challenge Dose in Subjects Who Received a Primary Neonatal Hepatitis B Vaccine.",,"Completed","Has Results","Hepatitis B","Biological: Engerix™-B","Number of Participants With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Above Specific Cut-off Values|Occurrence, Intensity and Relationship to Vaccination of Unsolicited Adverse Events (AEs)|Number of Participants Reporting Any Serious Adverse Events (SAEs).","GlaxoSmithKline","All","20 Years to 21 Years   (Adult)","Phase 4","76","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","108984","April 2007","January 2008","January 2008","April 5, 2007","May 15, 2009","December 16, 2016","GSK Investigational Site, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT00456625"
95,"NCT01102296","Effectiveness of Hepatitis A Virus Vaccination Among Homosexual Males at Risk for Hepatitis A Infection",,"Completed","No Results Available","Hepatitis","Biological: Hepatitis A vaccine","the proportion of vaccinees who achieve anti-HAV antibody concentrations of 20 mIU/ml or greater at week 48 of vaccination|the concentrations of anti-HAV antibody at week 48 of vaccination","National Taiwan University Hospital","Male","18 Years to 40 Years   (Adult)","Not Applicable","582","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","200903063M","June 2009","March 2012","April 2012","April 13, 2010",,"December 27, 2012","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01102296"
96,"NCT00141999","Response to Booster Doses of Hepatitis B Vaccine in Children and Adolescents",,"Completed","No Results Available","Hepatitis","Biological: hepatitis B vaccine",,"Centers for Disease Control and Prevention|Alaska Native Medical Center","All","5 Years to 14 Years   (Child)",,"400","U.S. Fed|Other","Observational","Time Perspective: Prospective","CDC-NCID-2998|U50/CCU022279","May 2001","March 2005","March 2008","September 2, 2005",,"September 27, 2012","Alaska Native Medical Center, Anchorage, Alaska, United States",,"https://ClinicalTrials.gov/show/NCT00141999"
97,"NCT05272735","HBV Vaccination of Healthy Volunteers to Evaluate the Composition of Germinal Centers",,"Recruiting","No Results Available","Hepatitis B","Biological: Hepatitis B Vaccine (Recombinant)","The Effects of HBV Vaccine on Memory B Cells|B Cell Response to the HBV Vaccination","Rockefeller University|Weill Medical College of Cornell University","All","18 Years to 50 Years   (Adult)","Phase 4","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","GVI 1028","December 10, 2022","December 30, 2024","June 30, 2025","March 9, 2022",,"January 24, 2024","The Rockefeller University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT05272735"
98,"NCT01341275","Adolescents' Response to Hepatitis B Vaccine Booster Dose","REACH","Unknown status","No Results Available","Hepatitis B","Biological: hepatitis B vaccine","anti-HBSAg titers","Baylor College of Medicine|Centers for Disease Control and Prevention","All","16 Years to 19 Years   (Child, Adult)","Phase 4","400","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","H-26257","April 2010","November 2011","November 2011","April 25, 2011",,"April 25, 2011","Texas Children's Hospital, Houston, Texas, United States|Texas Children's Pediatric Associates, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01341275"
99,"NCT02189603","Phase Ⅳ Clinical Trial of Recombinant Hepatitis E Vaccine（Hecolin®）",,"Completed","No Results Available","Hepatitis E","Biological: Recombinant (E. Coli) Hepatitis E Vaccine","Number of Participants with Serious and Non-Serious Adverse Events|anti-HEV IgG seropositive rate|GMT of anti-HEV IgG","Jun Zhang|Xiamen Innovax Biotech Co., Ltd|Xiamen Center for Disease Control and Prevention|Xiamen University","All","16 Years and older   (Child, Adult, Older Adult)","Phase 4","601","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PRO-HE-05","June 2014","December 7, 2015","December 7, 2015","July 14, 2014",,"August 17, 2018","Center for disease control and prevention in Xiamen haicang district, Xiamen, Fujian, China",,"https://ClinicalTrials.gov/show/NCT02189603"
100,"NCT03876470","Conquering Hepatitis C Via Micro-Elimination in Southwest Virginia","CHIME","Unknown status","No Results Available","Hepatitis C","Other: Hepatitis C treatment as chosen by provider","Cohort-level Hepatitis C Treatment Progress|Patient Reported Quality-of-Life|Depression|Health-Related Quality-of-Life|Semi-Structured Qualitative Interview about Impact of HCV Treatment","University of Virginia|Gilead Sciences","All","18 Years and older   (Adult, Older Adult)",,"300","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","21167","May 15, 2019","November 2020","November 30, 2020","March 15, 2019",,"April 17, 2019",,,"https://ClinicalTrials.gov/show/NCT03876470"
